Sirolimus Therapy in Tuberous Sclerosis or Sporadic Lymphangioleiomyomatosis

N Engl J Med. 2008 Jan 10;358(2):200-3. doi: 10.1056/NEJMc072500.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiomyolipoma / drug therapy*
  • Angiomyolipoma / etiology
  • Clinical Trials, Phase II as Topic
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / etiology
  • Lymphangioleiomyomatosis / complications*
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein Kinases / metabolism
  • Sirolimus / adverse effects
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases
  • Tuberous Sclerosis / complications*

Substances

  • Immunosuppressive Agents
  • Protein Kinase Inhibitors
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus